lonafarnib

GPTKB entity

Statements (34)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkb:drug
gptkbp:approvalYear 2020
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode L01XX72
gptkbp:CASNumber gptkb:193275-84-2
gptkbp:contraindication hypersensitivity to lonafarnib
gptkbp:developer gptkb:Eiger_BioPharmaceuticals
gptkb:Merck_&_Co.
gptkbp:firstBook yes
gptkbp:hasMolecularFormula C27H31N5O2
gptkbp:hasSMILES CC1=CC(=C(C=C1)NC(=O)C2=CC=CC=C2)C3=NC=NC(=N3)N4CCN(CC4)CCO
https://www.w3.org/2000/01/rdf-schema#label lonafarnib
gptkbp:indication progeroid laminopathies
gptkbp:KEGGID D09913
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction farnesyltransferase inhibitor
gptkbp:otherName gptkb:SCH66336
gptkb:Zokinvy
gptkbp:pregnancyCategory not recommended
gptkbp:PubChem_CID 16039398
CHEMBL1201832
DB06435
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gptkb:anemia
nausea
vomiting
diarrhea
fatigue
increased liver enzymes
gptkbp:UNII 6Z5B6HVF6O
gptkbp:usedFor treatment of Hutchinson-Gilford progeria syndrome
gptkbp:bfsParent gptkb:Harvey_rat_sarcoma_viral_oncogene_homolog
gptkbp:bfsLayer 6